BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hagan S, Orr MC, Doyle B. Targeted therapies in colorectal cancer-an integrative view by PPPM. EPMA J 2013;4:3. [PMID: 23356214 DOI: 10.1186/1878-5085-4-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Grech G, Zhan X, Yoo BC, Bubnov R, Hagan S, Danesi R, Vittadini G, Desiderio DM. EPMA position paper in cancer: current overview and future perspectives. EPMA J 2015;6:9. [PMID: 25908947 DOI: 10.1186/s13167-015-0030-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 8.0] [Reference Citation Analysis]
2 Kavousipour S, Khademi F, Zamani M, Vakili B, Mokarram P. Novel biotechnology approaches in colorectal cancer diagnosis and therapy. Biotechnol Lett 2017;39:785-803. [DOI: 10.1007/s10529-017-2303-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
3 Guo ST, Guo XY, Wang J, Wang CY, Yang RH, Wang FH, Li XY, Hondermarck H, Thorne RF, Wang YF, Jin L, Zhang XD, Jiang CC. MicroRNA-645 is an oncogenic regulator in colon cancer. Oncogenesis 2017;6:e335. [PMID: 28504690 DOI: 10.1038/oncsis.2017.37] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
4 Ann Kruger C, Abrahamse H. Targeted Photodynamic Therapy as Potential Treatment Modality for the Eradication of Colon Cancer. In: Jeong K, editor. Multidisciplinary Approach for Colorectal Cancer. IntechOpen; 2019. [DOI: 10.5772/intechopen.84760] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
5 Vishnubalaji R, Yue S, Alfayez M, Kassem M, Liu FF, Aldahmash A, Alajez NM. Bone morphogenetic protein 2 (BMP2) induces growth suppression and enhances chemosensitivity of human colon cancer cells. Cancer Cell Int 2016;16:77. [PMID: 27708551 DOI: 10.1186/s12935-016-0355-9] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
6 Golubnitschaja O, Costigliola V. EPMA summit 2014 under the auspices of the presidency of Italy in the EU: professional statements. EPMA J. 2015;6:4. [PMID: 25878761 DOI: 10.1186/s13167-015-0026-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
7 Grifantini R, Taranta M, Gherardini L, Naldi I, Parri M, Grandi A, Giannetti A, Tombelli S, Lucarini G, Ricotti L, Campagnoli S, De Camilli E, Pelosi G, Baldini F, Menciassi A, Viale G, Pileri P, Cinti C. Magnetically driven drug delivery systems improving targeted immunotherapy for colon-rectal cancer. Journal of Controlled Release 2018;280:76-86. [DOI: 10.1016/j.jconrel.2018.04.052] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 5.8] [Reference Citation Analysis]
8 Wang S, Wang L, Zhou Z, Deng Q, Li L, Zhang M, Liu L, Li Y. Leucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells. Sci Rep 2017;7:682. [PMID: 28386133 DOI: 10.1038/s41598-017-00839-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
9 Benarba B, Pandiella A. Colorectal cancer and medicinal plants: Principle findings from recent studies. Biomedicine & Pharmacotherapy 2018;107:408-23. [DOI: 10.1016/j.biopha.2018.08.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
10 Ryan E, Sheahan K, Creavin B, Mohan HM, Winter DC. The current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testing. Crit Rev Oncol Hematol. 2017;116:38-57. [PMID: 28693799 DOI: 10.1016/j.critrevonc.2017.05.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 12.4] [Reference Citation Analysis]
11 Abdul SN, Ab Mutalib NS, Sean KS, Syafruddin SE, Ishak M, Sagap I, Mazlan L, Rose IM, Abu N, Mokhtar NM, Jamal R. Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing. Front Pharmacol 2017;8:465. [PMID: 28769798 DOI: 10.3389/fphar.2017.00465] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
12 Pileri P, Campagnoli S, Grandi A, Parri M, De Camilli E, Song C, Ganfini L, Lacombe A, Naldi I, Sarmientos P, Cinti C, Jin B, Grandi G, Viale G, Terracciano L, Grifantini R. FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br J Cancer 2016;115:40-51. [PMID: 27328312 DOI: 10.1038/bjc.2016.145] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
13 Oliver Metzig M, Fuchs D, Tagscherer KE, Gröne H, Schirmacher P, Roth W. Inhibition of caspases primes colon cancer cells for 5-fluorouracil-induced TNF-α-dependent necroptosis driven by RIP1 kinase and NF-κB. Oncogene 2016;35:3399-409. [DOI: 10.1038/onc.2015.398] [Cited by in Crossref: 44] [Cited by in F6Publishing: 50] [Article Influence: 6.3] [Reference Citation Analysis]
14 Crucitta S, Cucchiara F, Mathijssen R, Mateo J, Jager A, Joosse A, Passaro A, Attili I, Petrini I, van Schaik R, Danesi R, Del Re M. Treatment-driven tumour heterogeneity and drug resistance: lessons from solid tumours. Cancer Treatment Reviews 2022. [DOI: 10.1016/j.ctrv.2022.102340] [Reference Citation Analysis]
15 Hodgkinson N, Kruger CA, Abrahamse H. Targeted photodynamic therapy as potential treatment modality for the eradication of colon cancer and colon cancer stem cells. Tumour Biol. 2017;39:1010428317734691. [PMID: 28990490 DOI: 10.1177/1010428317734691] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
16 Skeberdytė A, Sarapinienė I, Aleksander-Krasko J, Stankevičius V, Sužiedėlis K, Jarmalaitė S. Dichloroacetate and Salinomycin Exert a Synergistic Cytotoxic Effect in Colorectal Cancer Cell Lines. Sci Rep 2018;8:17744. [PMID: 30531808 DOI: 10.1038/s41598-018-35815-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
17 Haezam FN, Awang N, Kamaludin NF, Mohamad R. Synthesis and cytotoxic activity of organotin(IV) diallyldithiocarbamate compounds as anticancer agent towards colon adenocarcinoma cells (HT-29). Saudi J Biol Sci 2021;28:3160-8. [PMID: 34025187 DOI: 10.1016/j.sjbs.2021.02.060] [Reference Citation Analysis]
18 Hagan S, Martin E, Enríquez-de-Salamanca A. Tear fluid biomarkers in ocular and systemic disease: potential use for predictive, preventive and personalised medicine. EPMA J 2016;7:15. [PMID: 27413414 DOI: 10.1186/s13167-016-0065-3] [Cited by in Crossref: 115] [Cited by in F6Publishing: 98] [Article Influence: 19.2] [Reference Citation Analysis]
19 Zhou Y, Yang J, Zhang Q, Xu Q, Lu L, Wang J, Xia W. P4HB knockdown induces human HT29 colon cancer cell apoptosis through the generation of reactive oxygen species and inactivation of STAT3 signaling. Mol Med Rep 2019;19:231-7. [PMID: 30431122 DOI: 10.3892/mmr.2018.9660] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
20 Lu Y, Wang W, Wang J, Yang C, Mao H, Fu X, Wu Y, Cai J, Han J, Xu Z, Zhuang Z, Liu Z, Hu H, Chen B. Overexpression of arginine transporter CAT-1 is associated with accumulation of L-arginine and cell growth in human colorectal cancer tissue. PLoS One 2013;8:e73866. [PMID: 24040099 DOI: 10.1371/journal.pone.0073866] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
21 Lennon P, Deady S, Healy ML, Toner M, Kinsella J, Timon CI, O'Neill JP. Anaplastic thyroid carcinoma: Failure of conventional therapy but hope of targeted therapy. Head Neck 2016;38 Suppl 1:E1122-9. [PMID: 26879282 DOI: 10.1002/hed.24170] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
22 Yefimenko OY, Savchenko YO, Falalyeyeva TM, Beregova TV, Zholobak NM, Spivak MY, Shcherbakov OB, Bubnov RV. Nanocrystalline cerium dioxide efficacy for gastrointestinal motility: potential for prokinetic treatment and prevention in elderly. EPMA J 2015;6:6. [PMID: 25815090 DOI: 10.1186/s13167-015-0029-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
23 Konstantakou EG, Velentzas AD, Anagnostopoulos AK, Giannopoulou AF, Anastasiadou E, Papassideri IS, Voutsinas GE, Tsangaris GT, Stravopodis DJ. Unraveling the human protein atlas of metastatic melanoma in the course of ultraviolet radiation-derived photo-therapy. J Proteomics 2018;188:119-38. [PMID: 29180045 DOI: 10.1016/j.jprot.2017.11.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Cidon EU, Alonso P, Masters B. Markers of Response to Antiangiogenic Therapies in Colorectal Cancer: Where Are We Now and What Should Be Next? Clin Med Insights Oncol 2016;10:41-55. [PMID: 27147901 DOI: 10.4137/CMO.S34542] [Cited by in Crossref: 7] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
25 Šeklić DS, Obradović AD, Stanković MS, Živanović MN, Mitrović TL, Stamenković SM, Marković SD. Proapoptotic and Antimigratory Effects of Pseudevernia furfuracea and Platismatia glauca on Colon Cancer Cell Lines. Food Technol Biotechnol 2018;56:421-30. [PMID: 30510485 DOI: 10.17113/ftb.56.03.18.5727] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
26 Sardoiwala MN, Kushwaha AC, Dev A, Shrimali N, Guchhait P, Karmakar S, Roy Choudhury S. Hypericin-Loaded Transferrin Nanoparticles Induce PP2A-Regulated BMI1 Degradation in Colorectal Cancer-Specific Chemo-Photodynamic Therapy. ACS Biomater Sci Eng 2020;6:3139-53. [DOI: 10.1021/acsbiomaterials.9b01844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 O’brien O, Ryan É, Creavin B, Kelly ME, Mohan HM, Geraghty R, Winter DC, Sheahan K. Correlation of immunohistochemical mismatch repair protein status between colorectal carcinoma endoscopic biopsy and resection specimens. J Clin Pathol 2018;71:631-6. [DOI: 10.1136/jclinpath-2017-204946] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Rajarajan S, C E A, Jose B, Correa M, Sengupta S, Prabhu JS. Identification of colorectal cancers with defective DNA damage repair by immunohistochemical profiling of mismatch repair proteins, CDX2 and BRCA1. Mol Clin Oncol 2020;13:57. [PMID: 32953111 DOI: 10.3892/mco.2020.2128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Hoo WPY, Siak PY, In LLA. Overview of Current Immunotherapies Targeting Mutated KRAS Cancers. Curr Top Med Chem 2019;19:2158-75. [PMID: 31483231 DOI: 10.2174/1568026619666190904163524] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
30 Knickelbein K, Zhang L. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2015;2:4-12. [PMID: 25815366 DOI: 10.1016/j.gendis.2014.10.002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 59] [Article Influence: 8.4] [Reference Citation Analysis]
31 Koh B, Jeon H, Kim D, Kang D, Kim KR. Effect of fibroblast co-culture on the proliferation, viability and drug response of colon cancer cells. Oncol Lett 2019;17:2409-17. [PMID: 30675306 DOI: 10.3892/ol.2018.9836] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
32 Seol HS, Kang HJ, Lee SI, Kim NE, Kim TI, Chun SM, Kim TW, Yu CS, Suh YA, Singh SR. Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor. Cancer Lett. 2014;345:56-64. [PMID: 24333725 DOI: 10.1016/j.canlet.2013.11.010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
33 R M, P HA, Mahadevan V. HDAC inhibitors show differential epigenetic regulation and cell survival strategies on p53 mutant colon cancer cells. J Biomol Struct Dyn 2018;36:938-55. [PMID: 28264628 DOI: 10.1080/07391102.2017.1302820] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
34 Pinto N, Black M, Patel K, Yoo J, Mymryk JS, Barrett JW, Nichols AC. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. J Oncol 2014;2014:936285. [PMID: 25276134 DOI: 10.1155/2014/936285] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
35 Ghani S, Bahrami S, Rafiee B, Eyvazi S, Yarian F, Ahangarzadeh S, Khalili S, Shahzamani K, Jafarisani M, Bandehpour M, Kazemi B. Recent developments in antibody derivatives against colorectal cancer; A review. Life Sci 2021;265:118791. [PMID: 33220288 DOI: 10.1016/j.lfs.2020.118791] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
36 Caiazza F, Elliott L, Fennelly D, Sheahan K, Doherty GA, Ryan EJ. Targeting EGFR in metastatic colorectal cancer beyond the limitations of KRAS status: alternative biomarkers and therapeutic strategies. Biomark Med 2015;9:363-75. [PMID: 25808440 DOI: 10.2217/bmm.15.5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
37 Cháirez-Ramírez MH, Moreno-Jiménez MR, González-Laredo RF, Gallegos-Infante JA, Rocha-Guzmán NE. Lupane-type triterpenes and their anti-cancer activities against most common malignant tumors: A review. EXCLI J 2016;15:758-71. [PMID: 28337107 DOI: 10.17179/excli2016-642] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
38 Vatrano S, Pettinato A, Randazzo V, Zagami M, Agueli C, Cannella S, Banna GL, Fraggetta F, Santoro A. Diagnostic test assessment. Validation study of an alternative system to detect microsatellite instability in colorectal carcinoma. Pathologica 2020;112:178-83. [PMID: 32893846 DOI: 10.32074/1591-951X-113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Melincovici CS, Boşca AB, Şuşman S, Cutaş A, Mărginean M, Ilea A, Moldovan IM, Jianu EM, Neag MA, Bulboacă AE, Mihu CM. Assessment of mismatch repair deficiency, CDX2, beta-catenin and E-cadherin expression in colon cancer: molecular characteristics and impact on prognosis and survival - an immunohistochemical study. Rom J Morphol Embryol 2020;61:715-27. [PMID: 33817713 DOI: 10.47162/RJME.61.3.10] [Reference Citation Analysis]
40 Ahmad R, Alam M, Hasegawa M, Uchida Y, Al-Obaid O, Kharbanda S, Kufe D. Targeting MUC1-C inhibits the AKT-S6K1-elF4A pathway regulating TIGAR translation in colorectal cancer. Mol Cancer 2017;16:33. [PMID: 28153010 DOI: 10.1186/s12943-017-0608-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
41 Farinha P, Pinho JO, Matias M, Gaspar MM. Nanomedicines in the treatment of colon cancer: a focus on metallodrugs. Drug Deliv Transl Res 2021. [PMID: 33616870 DOI: 10.1007/s13346-021-00916-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Pesta M, Kucera R, Topolcan O, Karlikova M, Houfkova K, Polivka J, Macanova T, Machova I, Slouka D, Kulda V. Plasma microRNA Levels Combined with CEA and CA19-9 in the Follow-Up of Colorectal Cancer Patients. Cancers (Basel) 2019;11:E864. [PMID: 31234350 DOI: 10.3390/cancers11060864] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
43 Hu X, Huang W, Sun Z, Ye H, Man K, Wang Q, Sun Y, Yan W. Predictive factors, preventive implications, and personalized surgical strategies for bone metastasis from lung cancer: population-based approach with a comprehensive cancer center-based study. EPMA Journal. [DOI: 10.1007/s13167-022-00270-9] [Reference Citation Analysis]
44 Hudiță A, Radu IC, Zaharia C, Ion AC, Ginghină O, Gălățeanu B, Măruțescu L, Grama F, Tsatsakis A, Gurevich L, Costache M. Bio- and Hemo-Compatible Silk Fibroin PEGylated Nanocarriers for 5-Fluorouracil Chemotherapy in Colorectal Cancer: In Vitro Studies. Pharmaceutics 2021;13:755. [PMID: 34069731 DOI: 10.3390/pharmaceutics13050755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Suganya M, Gnanamangai BM, Ravindran B, Chang SW, Selvaraj A, Govindasamy C, Elsadek MF, Ponmurugan P. Antitumor effect of proanthocyanidin induced apoptosis in human colorectal cancer (HT-29) cells and its molecular docking studies. BMC Chem 2019;13:21. [PMID: 31384770 DOI: 10.1186/s13065-019-0525-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
46 Aziz MA, Yousef Z, Saleh AM, Mohammad S, Al Knawy B. Towards personalized medicine of colorectal cancer. Crit Rev Oncol Hematol. 2017;118:70-78. [PMID: 28917272 DOI: 10.1016/j.critrevonc.2017.08.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
47 Moussa M, Badawy A, Helal N, Hegab F, Youssef M, Aboushousha T, Al Faruok L, Elwy D. Differential Expression of HER2 and SKP2 in Benign and Malignant Colorectal Lesions. Asian Pac J Cancer Prev 2020;21:2357-66. [PMID: 32856866 DOI: 10.31557/APJCP.2020.21.8.2357] [Reference Citation Analysis]